Trials / Completed
CompletedNCT03054519
Improve PAD PERformance With METformin
Improve PAD Performance With Metformin: The PERMET Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 203 (actual)
- Sponsor
- Northwestern University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The PERMET trial will determine whether metformin daily for six months improves six-minute walk performance in individuals with peripheral artery disease compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin | Participants will be prescribed up to 2,000 mgs daily of metformin |
| DRUG | Placebo | Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators. |
Timeline
- Start date
- 2017-05-23
- Primary completion
- 2025-08-20
- Completion
- 2025-11-01
- First posted
- 2017-02-15
- Last updated
- 2026-04-15
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03054519. Inclusion in this directory is not an endorsement.